JCM
FOLD

Jafra Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Jafra Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-99,609
Closed -$1.56M – 33
2018
Q2 		$1.56M Sell
99,609
-20,000
-17% -$302K 0.54% 58
2018
Q1 		$1.8M Buy
119,609
+52,252
+78% +$795K 0.56% 53
2017
Q4 		$969K Buy
+67,357
New +$925K 0.27% 70

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jafra Capital Management's FOLD Position: Q3 2018 in Review

Jafra Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 99,609 shares — an estimated $1.56M sold.

Jafra Capital Management first reported a position in FOLD in Q4 2017 and held it in 3 quarters. The position peaked at $1.8M in Q1 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

  • Jafra Capital Management reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Jafra Capital Management sold 99,609 Amicus Therapeutics shares in Q3 2018, an estimated $1.56M.
  • Jafra Capital Management first reported a position in Amicus Therapeutics in Q4 2017 and held it in 3 quarters.
  • Jafra Capital Management's Amicus Therapeutics position peaked at $1.8M in Q1 2018.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Jafra Capital Management's 13F filing for Q3 2018.